Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-PEDV N/Nucleoprotein Polyclonal Antibody

Catalog #:   PVV28802 Specific References (52) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, IF, WB
Accession: Q07499
Overview

Catalog No.

PVV28802

Species reactivity

Porcine epidemic diarrhea virus (strain CV777) (PEDV)

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant PEDV N/Nucleoprotein (Met1-Asn441).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:200, IF: 1:50-1:200, WB: 1:500-1:4000

Target

Nucleoprotein, Nucleocapsid protein, NC, Protein N, N, 6

Concentration

0.85 mg/ml

Purification

Purified by antigen affinity column.

Accession

Q07499

Applications

ELISA, IHC, IF, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • Western Blot
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with PEDV N/Nucleoprotein antibody (PVV28802) at 1 µg/ml.

    Lane 1: Recombinant PEDV N/Nucleoprotein Protein(YVV28802)

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 60 kDa
    Observed MW: 60 kDa
References

Transcriptomic Profiling of Porcine Duodenal, Jejunal, and Ileal Organoids in Response to Porcine Epidemic Diarrhea Virus. [PVV28802]

Transcriptomic Profiling of Porcine Duodenal, Jejunal, and Ileal Organoids in Response to Porcine Epidemic Diarrhea Virus

First study to describe the prevalence and epidemiology of African swine fever, classical swine fever, porcine reproductive and respiratory syndrome and swine flu in Kazakhstan., PMID:40437487

Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma., PMID:40332715

Development of blocking ELISA for detection anti-PRRSV antibodies and serological investigation of PRRSV in China., PMID:39793838

A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories., PMID:39772242

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV., PMID:39644492

Pioneering molecular screening for cervical precursor lesions and cervical cancer in sera., PMID:39610929

Dynamics of Antibody Binding and Neutralization during Viral Infection., PMID:39609321

AIntibody: an experimentally validated in silico antibody discovery design challenge., PMID:39496931

Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses., PMID:39488210

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors., PMID:39385035

A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification., PMID:39383863

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens., PMID:39379400

Molecular imaging supports the development of multispecific cancer antibodies., PMID:39327536

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial., PMID:39284953

Multistage protective anti-CelTOS monoclonal antibodies with cross-species sterile protection against malaria., PMID:39209843

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals., PMID:39197450

Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil., PMID:39116904

Computationally designed mRNA-launched protein nanoparticle vaccines., PMID:39091730

Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls., PMID:39070044

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial., PMID:39038479

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines., PMID:38944664

The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study., PMID:38921803

Mono- and Bi-specific Nanobodies Targeting the CUB Domains of PCPE-1 Reduce the Proteolytic Processing of Fibrillar Procollagens., PMID:38901640

A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine., PMID:38900640

Anti-HIV Humoral Response Induced by Different Anti-Idiotype Antibody Formats: An In Silico and In Vivo Approach., PMID:38891926

NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma., PMID:38874333

Opposing effects of pre-existing antibody and memory T cell help on the dynamics of recall germinal centers., PMID:38838672

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study., PMID:38830991

Dynamics of antibody binding and neutralization during viral infection., PMID:38800656

Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands., PMID:38788210

Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity., PMID:38675770

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study., PMID:38657201

Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans., PMID:38490197

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals., PMID:38370696

Ultrasensitive Detection of PSA Using Antibodies in Crowding Polyelectrolyte Multilayers on a Silicon Nanowire Field-Effect Transistor., PMID:38337221

Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults., PMID:38294972

Improving stroke outcomes in hyperglycemic mice by modulating tPA/NMDAR signaling to reduce inflammation and hemorrhages., PMID:38190586

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines., PMID:38168207

Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine., PMID:38159648

Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation., PMID:38147543

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma., PMID:38084760

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates., PMID:38076895

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation., PMID:38052042

Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus., PMID:37989312

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study., PMID:37924050

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial., PMID:37919269

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)., PMID:37892566

Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18-60 and 60+ Age Cohorts., PMID:37766235

Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus., PMID:37745523

Neutralization, effector function and immune imprinting of Omicron variants., PMID:37648855

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-PEDV N/Nucleoprotein Polyclonal Antibody [PVV28802]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only